Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Abdominal pain, sometimes severe, is a known symptom of polycystic kidney disease (PKD)
related to the cystic expansion. This study will investigate whether the vasopressin V2
receptor antagonist lixivaptan can alleviate intractable pain in a pediatric PKD patient who
cannot tolerate the related vasopressin V2 receptor antagonist tolvaptan.